Atlas FDA

DAKOCYTOMATION EGFR PHARMDX

FDA premarket approval P030044 · decided 2004-02-12

Approval details

PMA number
P030044
Trade name
DAKOCYTOMATION EGFR PHARMDX
Generic name
Immunohistochemistry assay, antibody, epidermal growth factor receptor
Applicant
Agilent Technologies, Inc.
Date received
2003-09-29
Decision date
2004-02-12
Days to decision
136 days
Decision code
APWD
Product code
NQF
Advisory committee
Pathology
Expedited review
No
Location
Santa Clara, CA
Statement
APPROVAL FOR THE DAKOCYTOMATION EGFR PHARMDX. THE DEVICE IS INDICATED FOR: THE EGFR PHARMDX ASSAY IS A QUALITATIVE IMMUNOHISTOCHEMICAL (IHC) KIT SYSTEM TO IDENTIFY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXPRESSION IN NORMAL AND NEOPLASTIC TISSUES ROUTINELY-FIXED FOR HISTOLOGICAL EVALUATION. EGFR PHARMDX SPECIFICALLY DETECTS THE EGFR (HER1) PROTEIN IN EGFR-EXPRESSING CELLS. EGFR PHARMDX IS INDICATED AS AN AID IN IDENTIFYING COLORECTAL CANCER PATIENTS ELIGIBLE FOR TREATMENT WITH ERBITUX (CETUXIMA

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
GenetiSure Dx Postnatal Assay (K163367)Agilent Technologies, Inc.2017-08-11
MODIFICATION TO DEVICE LINK SYSTEM, MODEL M2376A (K012094)Agilent Technologies, Inc.2001-07-20
AGILENT M2636B TELEMON B MONITOR (TELEMON B) (K011824)Agilent Technologies, Inc.2001-07-02
HEARTSTREAM XL DEFIBIBRILLATOR/MONITOR, MODEL M4735A, HEARTSTREAM XLT DEFIBRILLATOR/MONITOR.MODEL M2500B (K010634)Agilent Technologies, Inc.2001-06-11
M2376A DEVICELINK SYSTEM, MODEL M2376A (K011578)Agilent Technologies, Inc.2001-06-08
HEARTSTREAM ATTENUATED DEFIBRILLATION PADS, MODEL M3870A (K003819)Agilent Technologies, Inc.2001-05-02
AGILENT INFORMATION CENTER SOFTWARE FOR M3150,M3151,M3153 AND M3154 (K011093)Agilent Technologies, Inc.2001-05-01
M2376A DEVICELINK SYSTEM (K010453)Agilent Technologies, Inc.2001-03-02